Horny H P, Marx L, Kröber S, Lüttges J, Kaiserling E, Dietl J
Institute of Pathology, University of Tübingen, Germany.
Gynecol Obstet Invest. 1999;47(2):133-8. doi: 10.1159/000010077.
Because the use of immunohistochemistry in the diagnosis of granulosa cell tumor (GCT) has not been fully explored, routinely processed (formalin-fixed, paraffin-embedded) tissue from 11 GCT, adult type, was investigated immunohistochemically (ABC method) with a broad spectrum of antibodies against various markers, including p53 and Ki-67. All of the tumors exhibited typical morphology, were limited to the ovary (stage I), and 7 cases followed a benign clinical course.
All the tumors exhibited strong expression of vimentin, but most other antigens (including smooth muscle actin) were expressed infrequently by a minority of tumor cells or not at all. Tumor cells in 9 GCT expressed inhibin A. All the tumors exhibited very low proliferative activity, fewer than 10% of the tumor cell nuclei being stained by the antibody MIB-1 (Ki-67 antigen). The antibody D07 revealed marked overexpression of p53 protein in only one tumor. Clinical outcome was not found to be related to immunophenotypic differences.
The diagnosis of GCT should be based primarily on the typical morphology revealed by conventional stains, but additional immunohistochemical staining with a small panel of selected antibodies (for example, against keratin, vimentin, and inhibin A) may be helpful in a few cases. The very low proliferative activity and the lack of overexpression of p53 protein are consistent with the benign clinical behavior of the majority of GCT.
由于免疫组织化学在颗粒细胞瘤(GCT)诊断中的应用尚未得到充分探索,本研究采用免疫组织化学方法(ABC法),使用多种针对不同标志物(包括p53和Ki-67)的广谱抗体,对11例成年型GCT的常规处理(福尔马林固定、石蜡包埋)组织进行了研究。所有肿瘤均表现出典型形态,局限于卵巢(I期),7例临床病程为良性。
所有肿瘤均显示波形蛋白强表达,但大多数其他抗原(包括平滑肌肌动蛋白)仅少数肿瘤细胞表达或完全不表达。9例GCT中的肿瘤细胞表达抑制素A。所有肿瘤均表现出极低的增殖活性,抗体MIB-1(Ki-67抗原)染色的肿瘤细胞核少于10%。抗体D07仅在1例肿瘤中显示p53蛋白明显过表达。未发现临床结果与免疫表型差异相关。
GCT的诊断应主要基于传统染色显示的典型形态,但在少数情况下,使用一小部分选定抗体(例如,针对角蛋白、波形蛋白和抑制素A)进行额外的免疫组织化学染色可能会有所帮助。极低的增殖活性和p53蛋白无过表达与大多数GCT的良性临床行为一致。